AstraZeneca Says Enhertu Demonstrates 14.3 Month Median Progression-Free Survival In Destiny-Lung04 Phase III Trial
AstraZeneca PLC LSE:AZN
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.